Antiemetics in chemotherapy
|
|
- Clifford Fletcher
- 6 years ago
- Views:
Transcription
1 Antiemetics in chemotherapy Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Directorate & Speciality Date of submission Date on which guideline must be reviewed (this should be one to three years) Explicit definition of patient group to which it applies (e.g. inclusion and exclusion criteria, diagnosis) Abstract Key Words Guideline for the prevention and management of nausea and vomiting in children and young people receiving chemotherapy Beverly Harwood, Paediatric Oncology Pharmacist, Katie Rogers, Clinical Educator, Ghazala Javid, Paediatric Oncology Pharmacist, Leicester Royal Infirmary Dani Jones, Clinical Educator Jenni Hatton, Paediatric Oncology Network Pharmacist Family Health, Paediatric Haematology/Oncology May 2015 May 2018 This guideline applies to all children and young people under the age of 19 years. This guideline describes the principles and management of nausea and vomiting in children and young adults receiving chemotherapy. antiemetic nausea vomiting chemotherapy; paediatrics; children 1a Statement of the evidence base of the guideline has the guideline been peer reviewed by colleagues? meta analysis of randomised controlled trials 2a at least one well-designed controlled study without randomisation 2b at least one other type of well-designed quasi-experimental study 3 well designed non-experimental descriptive studies (ie comparative / correlation and case studies) 4 expert committee reports or opinions and / or clinical experiences of respected authorities 5 recommended best practise based on the clinical experience of the guideline developer Consultation Process Target audience See references All paediatric oncology and haematology consultants, lead nurses, pharmacists and CYPICs Educator All clinical staff working in paediatric oncology to include doctors, nurses and pharmacists. This guideline has been registered with the trust. However, clinical guidelines are guidelines only. The interpretation and application of clinical guidelines will remain the responsibility of the individual clinician. If in doubt contact a senior colleague or expert. Caution is advised when using guidelines after the review date. Jenni Hatton Page 1 of 12 Version 5 May 2015
2 Document Control Issue Status Version Issue Date Lead Author V1 V2 Aug 2010 Beverly Harwood Paediatric Oncology Pharmacist V3 Aug 2013 Adam Henderson Paediatric Oncology Pharmacists. V4 Sept 2013 Beverly Harwood Paediatric Oncology Pharmacist V5 May 2015 Jenni Hatton Paediatric Oncology Pharmacist Dani Jones Clinical Educator for Children & Young People CYPICS Description Reviewed. Few changes Addition information regarding EMA warning about metoclopramide Amended first and second line treatments to comply with MHRA guidance on metoclopramide General Notes; This guideline is part of the CYPICS* documentation from *Children s and Young Peoples Integrated Cancer Service I can confirm that this guideline was reviewed by the members of the EMCYPICS team and, as its aim is for use by members of that team only, it has not received full circulation to all members of the Children s Hospital. Martin Hewitt Guideline Lead 22 June 2015 Jenni Hatton Page 2 of 12 Version 5 May 2015
3 Introduction Nausea and vomiting are two of the most distressing side effects of chemotherapy. Vomiting, in particular is a major concern for children and young people as this group are at particular risk of electrolyte imbalance, dehydration and weight loss. Not only do these factors place them at increased risk for future treatments but the emotional and physical distress caused to children, young people, and parents has a negative impact on their quality of life. It is therefore imperative that health professionals working with children and young people with cancer are able to provide suitable and effective antiemetic therapy. Emesis is a complex process that is mediated by both the central and peripheral nervous systems in response to several neurotransmitters including serotonin, dopamine, histamine, acetylcholine and neurokinin-1. Chemotherapy-induced nausea and vomiting is classified as anticipatory, acute and delayed. Anticipatory nausea and vomiting generally occurs before treatment commences and is triggered by taste, odour, sight, anxiety or if previous antiemetic control has been poor. Acute nausea and vomiting occurs up to 24 hours after treatment and delayed nausea and vomiting occurs from 24 hours to several days after treatment. Standard antiemetic regimes in Figure 2 may need adapting if anticipatory and/or delayed nausea and vomiting are experienced (see Figure 3 and 4). Principles Aim to minimise nausea and vomiting by administering anti-emetics regularly. For children who have not had chemotherapy before, first line antiemetic therapy should be selected based on the most emetogenic drug being given (see Figure 2). All children should receive antiemetic therapy according to the emetogenicity of the chemotherapy they are to receive and their previous experience of chemotherapy (see Figure 1). Always aim to use the oral route first if it is suitable. Consider starting antiemetics 24 hours prior to commencement of chemotherapy if child/young person has experienced chemotherapy-induced nausea and vomiting previously. Most children receive combination treatment with more than one drug, so the anti-emetic prescription should be based on the drug with highest emetogenic potential. However if two or more moderately emetogenic drugs are prescribed together then the emetogenicity of the course is increased and patients should be treated as if receiving highly emetogenic chemotherapy. Jenni Hatton Page 3 of 12 Version 5 May 2015
4 Figure 1: Antiemetic treatment choice Has the patient had prescribed chemotherapy agents previously? Yes No Was their antiemetic treatment successful?* Identify most emetogenic chemotherapy agent Yes No Prescribe regular antiemetics as per previous admission Prescribe regular antiemetics as per Figure 3 Prescribe regular antiemetics as per Figure 2 Has patient vomited and/or retched more than twice in 24 hours or experienced more than 4 hours of nausea? Yes No Add/change antiemetics as per Figure 4 Continue current antiemetics for this and subsequent admissions *Treatment is unsuccessful if child has vomited and/or retched more than twice in 24 hours or if they experienced more than 4 hours of nausea during chemotherapy Jenni Hatton Page 4 of 12 Version 5 May 2015
5 Figure 2a: First line antiemetic therapies Emetogenicity Chemotherapy Agent Recommended initial anti-emetic Low Asparaginase None Bevacizumab Fludarabine Mercaptopurine Methotrexate <50mg/m 2 Rituximab Vinblastine Vincristine Vinorelbine Moderate Bleomycin Ondansetron Oral / IV Cytarabine <100mg/m 2 <0.6m 2 1-2mg three times a day Etoposide m 2 4mg three times a day Gemcitabine >1.2m 2 8mg three times a day Methotrexate <5g/m 2 Topotecan N.B. If 2 moderately emetogenic drugs given together treat as per highly emetogenic chemotherapy. Start 30 to 60 minutes before chemo, repeat every 8-12 hours during chemotherapy and for at least 24 hours post chemo. High Very High Actinomycin Busulphan Cyclophosphamide <1000mg/m 2 Cytarabine mg/m 2 Daunorubicin Doxorubicin Epirubicin Idarubicin Irinotecan Methotrexate >5g/m 2 Procarbazine Temozolomide Carboplatin Carmustine Cisplatin Cyclophosphamide >1000mg/m 2 Cytarabine >500mg/m 2 Dacarbazine Ifosfamide Lomustine Under 12 years Ondansetron as above AND Domperidone Oral 1 month - 12yrs AND <35kg 250 microgram/kg three times a day > 12yrs or >35kg 10mg three times a day (max 30mg/day) 12 years and over Ondansetron as above AND Aprepitant oral >12 yrs AND >40kg 125mg once on day 1, one hour before the start of chemotherapy, then 80mg once daily on day 2 and day 3 of cycle. N.B if nausea & vomiting continues or oral route is not tolerated swap to; Metoclopramide IV for > 1 year old 0.15mg/kg three times a day (max 30mg / day) N.B. Contraindicated in <1yr old. Maximum 5 day duration (EMA recommendation August 2013). If <1yr use second line alternative. Under 12 years 12 years and over Ondansetron AND Metoclopramide Oral (first line) or IV (doses as above) +/- Ondansetron AND Aprepitant (as above) +/- Dexamethasone Oral / IV 2.5mg/m 2-5mg/m 2 twice to three times a day Round to nearest 0.5mg (max daily dose 10mg/m 2 ) N.B. Only to be used for a max total of 5 days. Discuss with consultant for patients with osteosarcoma or brain tumours. Do NOT use in patients receiving steroids as part of their chemotherapy. Jenni Hatton Page 5 of 12 Version 5 May 2015
6 Figure 2b: First line antiemetic therapies Drug and Preparation Ondansetron Tablets 4mg, 8mg Oral solution SF 4mg/5ml Ondansetron melt 4mg, 8mg Injection 2mg/ml Mechanism of action 5-HT 3 serotonin antagonist. Acts at the CTZ and in the GI tract. Side effects and comments Side effects: Headaches, constipation, flushing and occasional diarrhoea. Reduce dose in moderate / severe hepatic impairment. Less effective against delayed nausea and vomiting. Use metoclopramide / domperidone instead. Domperidone Tablet 10mg Suspension S/F 5mg/5ml Suppositories 30mg Aprepitant Capsules 120mg and 80mg Dexamethasone Tablets 500microgram and 2mg (can be dispersed) Oral solution S/F 2mg/5ml Injection 4mg/ml Metoclopramide Tablet 10mg Oral solution 5mg/5ml Injection 5mg/ml Antagonist of GI and central dopamine (D 2 ) receptors. Prokinetic properties. Use instead of metoclopramide for vomiting due to opioids or gastric stasis. Effective for delayed nausea and vomiting. Side effects: Rare extrapyramidal, rashes and rarely GI disturbances. Substance P Neurokinin receptor antagonist for prevention only; inhibits metabolism of dexamethasone reduce dose of dexamethasone by 50%. Prevents release of 5-HT 4 and 5-HT 3 in the GI. At low doses, Metoclopramide has dopamine antagonist (D 2 ) effect. At higher doses it has serotonin antagonist (5-HT 3, 5-HT 4 ) effect in the GI tract. PO 250micrograms/kg (max 20mg) TDS >12 years and >40kg 125mg orally once on day 1, then 80mg once daily on day 2 and day 3 of cycle. (max 7 days) Side effects: Insomnia, agitation, indigestion and mood and behaviour problems. Effective for delayed nausea and vomiting. Do NOT use in patients receiving steroids as part of their chemotherapy e.g. AML, ALL and BMT. Check with consultant for patients with osteosarcoma or brain tumours. It can help in delayed vomiting in children with CNS tumours who are receiving cisplatin (highly emetogenic) Side effects: Extrapyramidal (especially the young, < 10kg and girls) and sedation. Dystonic reactions more likely when daily dose exceeds 500 micrograms/kg. Contraindicated in < 1 year old and maximum 5 day duration due to concerns over side effects and efficacy (EMA recommendation August 2013) Procyclidine or benzatropine can be used to reverse its adverse effects. Can be useful in severe intractable vomiting due to radiotherapy and cytotoxics. Jenni Hatton Page 6 of 12 Version 5 May 2015
7 If a child vomits and/or retches more than twice in 24 hours, or has more than 4 hours of nausea add in further first line medication or change to/add a second line antiemetic (see Figure 4). If control is still unsatisfactory, discuss the addition of a further agent with senior medical staff and consider other possible causes of emesis (see Investigations). Anticipatory nausea and vomiting may be helped by the administration of lorazepam or other anxiolytic treatment hours before chemotherapy, particularly in adolescent patients. Non-drug therapies such as distraction, breathing techniques and muscle relaxation can also be helpful. Figure 3: Second line antiemetic choice (For extra information/doses see Figure 4) Is patient on maximal first line therapy? No Prescribe additional first line antiemetic (Fig. 2) Yes Does nausea/vomiting have anxiety component? Yes Consider lorazepam if > 12 years No Is nausea and vomiting controlled? No Consider other causes for nausea/vomiting and discuss following options with senior medical staff: 1. Add in domperidone if not already on. 2. Add levomepromazine in place of metoclopramide 3. Add cycllizine 4. Switch from ondansetron to granisetron (if stocked locally) 5. Other options to consider: a. Haloperidol (in place of levomepromazine and domperidone) b. Prochlorperazine c. Continuous granisetron infusion d. Nabilone e. Hyoscine Patches Ensure the anti-emetics for the following cycles are amended to reflect the successful treatment. Jenni Hatton Page 7 of 12 Version 5 May 2015
8 Figure 4: Second line antiemetic therapies Drug and Preparation Cyclizine Tablets 50mg (can be crushed) Injection 50mg/ml Granisetron Tablets 1mg Injection 1mg/ml Haloperidol Capsule 500microgram Scored Tablets 0.5mg, 1.5mg, 5mg,10mg, 20mg Oral liquid 1mg/ml, 2mg/ml and SP 1mg/5ml Injection 5mg/ml Levomepromazine Tablets 6mg (SP) and 25mg (can be halved or crushed) Injection 25mg/ml Indication, action, side effects and general comments. Antihistamine (H 1 receptor) with antimuscarinic properties. No evidence for use in chemotherapy induced nausea and vomiting, but has been used in other centres. Cyclizine can be used with metoclopramide but this should be discussed with the ward pharmacist. Can be useful in vomiting due to raised intracranial pressure, intractable vomiting due to vestibular disorders, palliative care, irradiation sickness or opiate-induced vomiting. Side effects: Drowsiness, dry mouth, blurred vision and rash. 5 HT 3 antagonist. Treat/prevent acute and delayed CINV. Can be used instead of ondansetron if other first line therapies failed/unsuitable; Can give total daily dose as continuous IV infusion if effect wears off between doses. Side effects: Constipation, headache, rash and transient increase in liver enzymes. Drug of choice for vomiting due to renal/hepatic failure, and hypercalcaemia. Useful in opiate induced vomiting or intractable vomiting in palliative care. Side effects: Less sedating, extrapyramidal symptoms including dystonic reactions and akathisia A phenothiazine with effects at dopamine (D 2 ), histamine (H 1 ), muscarinic and 5HT 2 receptors. Can be useful in vomiting due to raised intracranial pressure. Has moderate sedating action. Used for delayed and refractory nausea and vomiting. Side effect: Sedation can be significant. Postural hypotension and constipation. Injection site reaction and occasionally raised ESR occurs. Carefully monitor patients receiving Ifosfamide since sedation may mask signs of encephalopathy. Dose: includes route and frequency. Oral / IV 1 month 6 years mg/kg three times a day (max. single dose 25mg) 6-12 years 25mg three times a day years 50mg three times a day Oral: 20micrograms/kg (max 1mg) twice to three times a day IV 40micrograms/kg (max 3mg) twice to three times a day Oral >12 years 1.5mg once daily at night; increased to twice a day if necessary, up to a maximum of 5mg twice a day IV / SC continuous infusion 25-85micrograms/kg (max 5mg) over 24 hours Oral 2-12 years mg/kg (max 25mg) once or twice a day. >12 years mg once or twice a day. SC / IV bolus doses mg/kg twice a day or 0.1mg/kg daily IV / SC continuous infusion micrograms/kg (max 25mg) over 24 hours Jenni Hatton Page 8 of 12 Version 5 May 2015
9 Drug and Preparation Lorazepam Tablets 1mg, 2.5mg Injection 4mg/ml (can be given sublingually). Indication, action, side effects and general comments A short acting benzodiazepine with minimal anti-emetic effects but can be used for its amnesic and anxiolytic properties. It has been used for anticipatory nausea and vomiting the night before chemotherapy is due. Enhanced sedation or respiratory and cardiovascular depression may occur if benzodiazepines are given with CNS depressants e.g. anaesthetics, opioids, antihistamines and anxiolytics. Dose: includes route and frequency. Oral >12 years 1-2mg once or twice a day Anticipatory nausea/vomiting aged 5-10 years: 0.5mg as a single dose. Give the night before and/or the morning of chemo. Breakthrough emesis: micrograms/kg/dose 6 hourly (max 4mg dose, but 2mg often sufficient) Nabilone Capsule 1mg Prochlorperazine Oral Syrup 5mg/5ml Tablets 5mg Buccal Tablets 3mg Injection 12.5mg/ml Hyoscine Hydrobromide patches Scopoderm TTS 1mg/72 hours release transdermal patch A cannabinoid drug with central action. Used in adolescents when refractory to dexamethasone and ondansetron. It is used for acute, delayed and refractory emesis. Start the night before, duration of chemo and until 48 hours after chemo. Side effects: dizziness, drowsiness, behavioural alterations, dry mouth, ataxia, postural hypotension. Hallucinations, euphoria and other psychotic reactions in some patients. Patients and carers should be made aware of possible changes in mood and other adverse behavioural effects. Dopamine agonist that acts centrally and blocks CTZ. Useful in opioid induced nausea and vomiting. Used for refractory anticipatory emesis and intractable vomiting of unknown cause. Anticholinergic muscarinic antagonist. It is used for refractory chemotherapy induced nausea and vomiting. Use with care in patients on other anticholinergic and CNS acting drugs. Prokinetic effect of metoclopramide and domperidone is antagonised. Side effects: drowsiness, dry mouth, dizziness, blurred vision, difficulty with micturition. Local irritation so rotate application site. Oral <18kg 0.5mg twice a day 18-30kg 1mg twice a day >30kg 1mg three times a day Oral 1-12 years 250micrograms/kg (max 10mg) three times a day >12 years 5-10mg three times a day BUCCAL >12 years 3-6mg twice a day IM 2-5 years 1.25mg - 2.5mg three times a day 5-12 years mg three times a day >12 years 12.5mg TDS 1 month to 3 years 250 microgram /72 hour (1/4 patch) 3-10 years 500 microgram/72 hours (1/2 patch) years 1mg/72 hours 1 patch Apply 12 hours before chemotherapy. Patches can be cut with scissors and applied to hairless skin behind ear. Jenni Hatton Page 9 of 12 Version 5 May 2015
10 Clinical Assessment The assessment of children and young people with chemotherapy-induced nausea and vomiting (CINV) can be difficult and complex. Children may not understand what they are being asked to describe, particularly in relation to nausea, and/or may not have the vocabulary to explain the symptoms they are experiencing. Therefore, discuss these issues with the nursing team and parents to assess children for signs and symptoms of CINV. History Key areas/questions to consider when taking a history from the child, parent and/or nurse include: Have they experienced any anticipatory vomiting (vomiting that usually occurs up to 12 hours before chemotherapy is commenced)? Has the child experienced CINV previously? Has previous antiemetic therapy been effective? Is the child or young person particularly anxious about their treatment or CINV? If so, the use of distraction and relaxation techniques, complementary therapies, psychological input and/or lorazepam may need to be considered and discussed with senior medical staff. Has the child experienced any change in appetite or mood that coincides with chemotherapy treatment? In pre-verbal children, these could be indicators of significant nausea. On examination When examining a child for signs and symptoms of CINV, the following may be evident: Pallor Tachycardia Dizziness Perspiration Anorexia Excess salivation Dehydration It is essential to assess the child s fluid balance, not only to identify dehydration but to ascertain whether the antiemetic therapy is successful or is in need of modification as per Figure 3. Follow up The efficacy and needs for antiemetic therapy should be reviewed by the clinical team at least every three months while on a chemotherapy regime. Discharge medication Regular antiemetics should be continued for the duration of chemotherapy and for 3 days afterwards. Children receiving low emetogenic chemotherapy do not require further antiemetic medication, unless they have experienced previous problems with delayed vomiting. Children receiving moderately emetogenic chemotherapy should initially be given a course of ondansetron to continue for two days after the end of chemotherapy. Children under 12 years of age receiving highly emetogenic chemotherapy should be given ondansetron with dexamethasone (unless the latter contraindicated). Dexamethasone should only be given for a total of 5 days. A five-day supply of domperidone to be taken when required should also be prescribed and dispensed. Children under 12 years of age receiving very highly emetogenic chemotherapy should be given ondansetron with dexamethasone (unless the latter contraindicated). Dexamethasone should only be given for a total of 5 days. A five-day supply of metoclopramide to be taken only if needed should also be prescribed and dispensed. Jenni Hatton Page 10 of 12 Version 5 May 2015
11 Children 12 years and older receiving highly or very highly emetogenic chemotherapy will have aprepitant for up to seven days to cover the course of chemotherapy plus 2 further days. They should also be given a supply of ondansetron and dexamethasone (unless the latter is contraindicated as above). If vomiting persists for longer than 7 days then metoclopramide or domperidone should be used as these are more effective than 5HT 3 antagonists for long term use. References 1. Emend 80mg and 125mg hard capsules. Summary of Product Characteristics. Available at accessed 19 th January Joint Formulary Committee. BNFc London, BMJ Group, RPS Publishing, PCPCH Publishing 3. Hawkins R and Grunberg S. Chemotherapy-induced nausea and vomiting: challenges and opportunities for improved patient outcomes. Clin J Onc Nursing 2009; 13(1): National Institute for Health and Clinical Excellence. Improving outcomes in children and young people with cancer. Available at accessed 15 th December Dupuis L and Nathan P. Options for the prevention and management of acute chemotherapy-induced nausea and vomiting in children. Pediatr Drugs 2003; 5(9): Tramer M et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2001; 323: Smith A et al. Aprepitant for the control of chemotherapy induced nausea and vomiting in adolescents. Pediatr Blood Cancer 2005; 45: Schmoll H et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Onc 2006; 17: Antonarakis E et al. Prophylaxis of acute chemotherapy-induced nausea and vomiting in children with cancer: what is the evidence? Pediatr Blood Cancer 2004; 43: Holdsworth M et al. Acute and delayed nausea and emesis control in pediatric oncology patients. Cancer 2006; 106(4): Roila F et al. Prevention of chemotherapy and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Onc 2006; 17: Molassiotis A et al. A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre. Support Care Cancer 2008; 16: Small B et al. Survey ranking of emetogenic control in children receiving chemotherapy. J Ped Hem/Onc 2000; 22(2): Schnell F. Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. The Oncologist 2003; 8: Jordan K, Sippel C and Schmoll H. Guidelines for antiemetic treatment of chemotherapyinduced nausea and vomiting: past, present and future recommendations. The Oncologist 2007; 12: Hesketh P. Chemotherapy-induced nausea and vomiting. N Eng J Med 2008; 358(23): Giglio A et al. Granisetron is equivalent to ondansetron for prophylaxis of chemotherapyinduced nausea and vomiting. Cancer 2000; 89(11): Jassal SS, Hain R. The Association of Paediatric Palliative Medicine Master Formulary Jenni Hatton Page 11 of 12 Version 5 May 2015
12 Appendix 1: Graph to show relative costs of 24 hours antiemetic therapy. APREPITANT 125mg OD APREPITANT 80mg OD Dexamethasone 2mg TDS IV Dexamethasone 2mg TDS PO TAB Dexamethasone 4mg TDS IV Dexamethasone 4mg TDS PO TAB Domperidone 10mg TDS PO SYRUP Domperidone 10mg TDS PO TAB Domperidone 5mg TDS PO SYRUP Domperidone 5mg TDS PO TAB Granisetron 1mg BD IV Granisetron 1mg BD PO TAB Granisetron 3mg TDS IV Haloperidol 1.5mg PO OD TAB Lorazepam 1mg BD PO TAB Metoclopramide 10mg TDS IV Metoclopramide 10mg TDS PO SYRUP Metoclopramide 10mg TDS PO TABS Metoclopramide 5mg TDS IV Metoclopramide 5mg TDS PO SYRUP Metoclopramide 5mg TDS PO TABS Nabilone 0.5mg BD PO Nabilone 1mg BD PO Ondansetron 2mg TDS IV Ondansetron 2mg TDS PO SYRUP Ondansetron 2mg TDS PO TABS Ondansetron 4mg TDS IV Ondansetron 4mg TDS PO SYRUP Ondansetron 4mg TDS PO TABS Jenni Hatton Page 12 of 12 Version 5 May 2015
Job title: Consultant Pharmacist/Advanced Practice Pharmacist
Title : Guidelines for the Use of Antiemetics Purpose: To provide trust-wide guidance on the safe and effective use of antiemetics for the prevention and treatment of chemotherapy and radiotherapy induced
More informationWest of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting
West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting Definitions Acute nausea and vomiting Delayed nausea and vomiting Anticipatory nausea and vomiting Initial
More informationGuidelines for the Use of Anti-Emetics with Chemotherapy
Guidelines for the Use of Anti-Emetics with The purpose of this document is to provide guidance on the rational use of anti-emetics for prevention and treatment of chemotherapy-induced nausea and vomiting
More informationGUIDELINE FOR THE MANAGEMENT OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING.
Page 1 of 20 Guideline for the management of chemotherapy-induced nausea and vomiting, v2.1.1 GUIDELINE FOR THE MANAGEMENT OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING. Version: 2.1.0 Ratified by: Date
More informationCLINICAL GUIDELINE FOR ANTIEMETIC USE IN PAEDIATRIC ONCOLOGY 1. Aim/Purpose of this Guideline
CLINICAL GUIDELINE FOR ANTIEMETIC USE IN PAEDIATRIC ONCOLOGY 1. Aim/Purpose of this Guideline 1.1. This guideline applies to medical and nursing staff working with paediatric oncology patients. 2. The
More informationChemotherapy Induced Nausea and Vomiting (CINV) Anti-emetic Guidelines
North of England Cancer Network Chemotherapy Induced Nausea and Vomiting (CINV) Anti-emetic Guidelines Adult Oncology & Haematology Quality and safety for every patient every time For more information
More informationGUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION
GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY More than half of all cancer patients experience nausea or vomiting during the course of their treatment. If nausea or vomiting becomes severe enough,
More informationTrust Guideline for Prevention and Control of Chemotherapy and Radiotherapy Induced Nausea and Vomiting in Adults
A Clinical Guideline For Use in: Organisation-wide By: For: Key words: Name of document author: Job title of document author: Name of document author s Line Manager: Job title of author s Line Manager:
More informationGuideline Update on Antiemetics
Guideline Update on Antiemetics Clinical Practice Guideline Special Announcements Please check www.asco.org/guidelines/antiemetics for current FDA alert(s) and safety announcement(s) on antiemetics 2 Introduction
More informationPrevention of Antineoplastic Medication induced Nausea and Vomiting in Pediatric Cancer Patients
Prevention of Antineoplastic Medication induced Nausea and Vomiting in Pediatric Cancer Patients Done by :Meznah Zaid Al-Mutairi Pharm.D Candidate PNU University College of Pharmacy Introduction Nausea
More informationMASCC Guidelines for Antiemetic control: An update
MASCC / ISOO 17 th International Symposium Supportive Care in Cancer June 30 July 2, 2005 / Geneva, Switzerland MASCC Guidelines for Antiemetic control: An update Sussanne Börjeson, RN, PhD Linköping University,
More informationClinical Policy: Dolasetron (Anzemet) Reference Number: ERX.NPA.83 Effective Date:
Clinical Policy: (Anzemet) Reference Number: ERX.NPA.83 Effective Date: 09.01.18 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationNorthern Cancer Alliance
Northern Cancer Alliance Anti-emetic Guidelines for Chemotherapy Induced Nausea and Vomiting (CINV) Adult Oncology & Haematology Document Control Document Title: Antiemetic Guidelines for CINV NESCN v2.2
More informationGI Pharmacology -4 Irritable Bowel Syndrome and Antiemetics. Dr. Alia Shatanawi
GI Pharmacology -4 Irritable Bowel Syndrome and Antiemetics Dr. Alia Shatanawi 11-04-2018 Drugs used in Irritable Bowel Syndrome Idiopathic, chronic, relapsing disorder characterized by abdominal discomfort
More informationCLINICAL GUIDANCE FOR THE PREVENTION AND MANAGEMENT OF CHEMOTHERAPY AND RADIOTHERAPY INDUCED NAUSEA AND VOMITING IN ADULTS
CLINICAL GUIDANCE FOR THE PREVENTION AND MANAGEMENT OF CHEMOTHERAPY AND RADIOTHERAPY INDUCED NAUSEA AND VOMITING IN ADULTS Procedure reference: Document owner: 2196 Version: V2.1 Robert Duncombe, The Director
More informationGuidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients
Guidelines on Chemotherapy-induced Nausea Vomiting in Pediatric Cancer Patients COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive Care Endorsed Guidelines. DISCLAIMER For
More informationClinical Policy: Nabilone (Cesamet) Reference Number: ERX.NPA.35 Effective Date:
Clinical Policy: (Cesamet) Reference Number: ERX.NPA.35 Effective Date: 09.01.17 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationAPPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer
APPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer 5850/5980 University Avenue, PO Box 9700, Halifax, N.S. B3K 6R8 PEDIATRIC HEMATOLOGY/ONCOLOGY
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Anzemet) Reference Number: CP.PMN.141 Effective Date: 09.01.06 Last Review Date: 08.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
More informationSystemic Anti-cancer Therapy Care Pathway Guidelines for the management of SACT induced nausea and vomiting in adult patients
Systemic Anti-cancer Therapy Care Pathway Guidelines for the management of SACT induced nausea and vomiting in adult patients Pathway of Care Kent & Medway Cancer Collaborative Publication date June 2018
More informationNausea and Vomiting in Palliative Care
Nausea and Vomiting in Palliative Care Definitions Nausea - an unpleasant feeling of the need to vomit Vomiting - the expulsion of gastric contents through the mouth, caused by forceful and sustained contraction
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Cesamet) Reference Number: CP.PMN.160 Effective Date: 11.16.16 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationECN Protocol Book. Antiemetic Guidelines for Adult Patients Receiving Chemotherapy and Radiotherapy
ECN Protocol Book Antiemetic Guidelines f Adult Patients Receiving Chemotherapy and Radiotherapy Name of person presenting document: Reason f document development: Names of development team: Specify groups
More informationManaging Adverse Events in the Cancer Patient. Learning Objectives. Chemotherapy-Induced Nausea/Vomiting
Managing Adverse Events in the Cancer Patient Lisa A Thompson, PharmD, BCOP Assistant Professor University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Learning Objectives Describe
More informationUpdates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017
Updates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017 MELISSA C. MACKEY, PHARMD, BCPS, BCOP ONCOLOGY CLINICAL PHARMACIST DUKE UNIVERSITY HOSPITAL AUGUST 5, 2017 Objectives Review risk factors
More informationClinical Policy: Ondansetron (Zuplenz) Reference Number: CP.PMN.45 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Zuplenz) Reference Number: CP.PMN.45 Effective Date: 09.01.06 Last Review Date: 02.19 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationDrug: Aprepitant (Emend ) Date of Review: 4/01/10
CAMBRIDGESHIRE JOINT PRESCRIBING GROUP Business Case Evaluation and Recommendation Document Drug: Aprepitant (Emend ) Date of Review: 4/01/10 Business Case Decision and date: DOUBLE RED, 20 January 2010
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Kytril, Sancuso, Sustol) Reference Number: CP.PMN.74 Effective Date: 11.01.16 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important
More informationPAIN AND SYMPTOM MANAGEMENT GUIDANCE IN THE LAST DAYS OF LIFE
PAIN AND SYMPTOM MANAGEMENT GUIDANCE IN THE LAST DAYS OF LIFE Reference: DCM029 Version: 1.1 This version issued: 07/06/18 Result of last review: Minor changes Date approved by owner (if applicable): N/A
More informationSupporting Last Days of Life Symptom Control Medication Guidance: Algorithm. Agitation & Anxiety
Agitation & Anxiety (Exclude or treat REVERSIBLE causes*) Patient is anxious / frightened, but lucid Patient is confused, agitated and / or hallucinating MIDAZOLAM 2.5-5mg s/c (Max total 24 hour dose of
More informationManagement of Nausea and Vomiting
June 01, 2015 By Rudolph M. Navari, MD, PhD, FACP [1] Although marked progress in controlling chemotherapy-induced emesis has occurred over the past 25 years, nausea and vomiting remain among the most
More informationManagement of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients
Management of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients By Zahra Shaghaghi, Pharm-D, BCOP, PhC Prepared for 2018 NMSHP Balloon Fiesta Symposium Goals and Objectives: Describe
More informationManagement of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients
Management of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients By Zahra Shaghaghi, Pharm-D, BCOP, PhC Prepared for 2018 NMSHP Balloon Fiesta Symposium 1 Goals and Objectives: Describe
More informationBACKGROUND Measuring renal function :
A GUIDE TO USE OF COMMON PALLIATIVE CARE DRUGS IN RENAL IMPAIRMENT These guidelines bring together information and recommendations from the Palliative Care formulary (PCF5 ) BACKGROUND Measuring renal
More informationSYMPTOM MANAGEMENT GUIDANCE FOR PATIENTS RECEIVING PALLIATIVE CARE AT ROYAL DERBY HOSPITAL
SYMPTOM MANAGEMENT GUIDANCE FOR PATIENTS RECEIVING PALLIATIVE CARE AT ROYAL DERBY HOSPITAL If a patient is believed to be approaching the end of their life, medication should be prescribed in anticipation
More informationManagements of Chemotherpay Induded Nausea and Vomiting
REVIEW ARTICLE Managements of Chemotherpay Induded Nausea and Vomiting Department of Surgery, The Catholic University of Korea Sung Geun Kim 23 24 Sung Geun Kim Korean Journal of Clinical Oncology Summer
More informationEmetogenicity level 1. Emetogenicity level 2
Emetogenicity level 1 15 mins Pre-Chemo Maxalon 10mg po During chemo and Post Chemo 3 days Maxalon10mg po 8 hourly Increase Maxalon 20mg po 8 hourly Change to Cyclizine 50mg po 8 hourly 3 days If nausea
More informationPAEDIATRIC DOSAGE GUIDELINES For management of post-operative acute pain
Index No: MMG43 PAEDIATRIC DOSAGE GUIDELINES For management of post-operative acute pain Version: 3.1 (Includes anti-emetics and naloxone) Date ratified: July 2013 Ratified by: (Name of Committee) Name
More informationCare in the Last Days of Life
Care in the Last Days of Life Introduction This guideline is an aid to clinical decision making and good practice in person-centred care for patients who are deteriorating and at risk of dying. The patient
More informationTRANSPARENCY COMMITTEE OPINION. 31 January Date of marketing authorisation: 22 March 2005 (centralised marketing authorisation)
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 31 January 2007 ALOXI 250 µg solution for injection B/1 CIP 375,482-8 Applicant: THERABEL LUCIEN PHARMA palonosetron
More informationSupportive care session 1:
Board review in oncology pharmacy 2013 Managing Disease or Treatment Related Complication Supportive care session 1: Chemotherapy induced-nausea and vomiting Suthan Chanthawong, B. Pharm, RPh. Objectives
More informationVI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies:
VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Incidence: The incidence of acute and delayed N&V was investigated in highly and moderately emetogenic
More informationCorporate Medical Policy
Antiemetic Injection Therapy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: antiemetic_injection_therapy 5/2015 3/2017 3/2018 3/2017 Description of Procedure
More informationSCI. SickKids-Caribbean Initiative Enhancing Capacity for Care in Paediatric Cancer and Blood Disorders
1.0 Introduction The (SCI) is a not-for-profit collaboration between the Hospital for Sick Children (SickKids), Toronto, Canada, and seven Caribbean health care institutions across six countries that strive
More informationAntiemetics: Guidelines, Interactions and more.
Antiemetics: Guidelines, Interactions and more. Chemotherapy-induced side effects -the patient s view Loss of hair The thought of coming for chemo Affects family/partner Affects work/home duties Jude Lees
More informationSyringe driver in Palliative Care
Syringe driver in Palliative Care Introduction: Syringe drivers are portable, battery operated devices widely used in palliative care to deliver medication as a continuous subcutaneous infusion over 24
More informationConflicts of Interest. Review of Antiemetic Guidelines. Learning Objectives. What is Emesis Anyways? Pharmacy Technician Learning Objectives
Conflicts of Interest No financial relationships to disclose Review of Antiemetic Guidelines Matthew Fox, PharmD, BCPS, BCOP Clinical Oncology Pharmacist Baptist MD Anderson Jacksonville, Florida October
More informationClinical Guideline for the management of inpatients with Parkinson s disease
Clinical Guideline for the management of inpatients with Parkinson s disease Introduction: Parkinson s disease (PD) is the second most common neurodegenerative disorder, characterised by bradykinesia,
More informationATTUALITÀ NEL CONTROLLO DELL EMESI
ATTUALITÀ NEL CONTROLLO DELL EMESI Dr Claudio Lotesoriere Dipartimento di Oncoematologia S.C. di Oncologia Medica P.O. San G. Moscati TARANTO email oncologia.taranto@gmail.com Types of CINV: Definitions
More informationDECONTAMINATION AGENTS and ANTIEMETICS *** This material won t be covered in lecture, but you are responsible for it***
Decontamination and Antiemetics Med 5724 Page 1 of 8 DECONTAMINATION AGENTS and ANTIEMETICS *** This material won t be covered in lecture, but you are responsible for it*** REFERENCES: Katzung (9th ed.)
More informationCHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING Jennifer Shamai MS, RN, AOCNS, BMTCN Professional Practice Leader Department of Clinical Practice And Professional Education Click How to the edit Experts Master
More informationPrevention and Management of cancer disease and of chemo-and radiotherapyinduced nausea and vomiting
Prevention and Management of cancer disease and of chemo-and radiotherapyinduced nausea and vomiting Focusing on the updated MASCC/ESMO guidelines Karin Jordan Department of Hematology and Oncology, University
More informationControlling nausea and vomiting: anti-emetic therapy advice
Controlling nausea and vomiting: anti-emetic therapy advice Chemotherapy A guide for patients and carers Contents Treatments that may cause nausea and vomiting... 2 Physical reasons that may cause nausea
More informationNausea & Vomiting. Dr Eve Lyn TAN Liverpool Hospital NSW, AUSTRALIA
Nausea & Vomiting Dr Eve Lyn TAN Liverpool Hospital NSW, AUSTRALIA Prevalence prevalence varies *, systemic review 2007 : overall prevalence : nausea 30%, vomiting 20% in last 1-2 weeks of life : nausea
More informationPrevention of chemotherapy induced nausea and vomiting in pediatric cancer patients
REVIEW ARTICLE Prevention of chemotherapy induced nausea and vomiting in pediatric cancer patients Shubham Roy 1, Rashi Kulshrestha 2, Abhishek Shankar 3, Goura Kishor Rath 4, Vipin Kharade 4 1 Department
More informationAntiemesis. NCCN Clinical Practice Guidelines in Oncology. Antiemesis. Version Continue
Table of Contents Clinical in Oncology Version 2.2010 Continue www.nccn.org Version 2.2010, 04/07/2010 2010 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration
More informationReview Article Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting
Hindawi Publishing Corporation BioMed Research International Volume 2015, Article ID 595894, 6 pages http://dx.doi.org/10.1155/2015/595894 Review Article Treatment of Breakthrough and Refractory Chemotherapy-Induced
More informationConservative Management of Uraemia
Conservative Management of Uraemia Information for Health Professionals Renal Department The York Hospital and Scarborough Hospital Tel: 01904 725370 For more information, please contact: The Renal Specialist
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Antiemetic Therapy Table of Contents Coverage Policy... 1 General Background... 6 Coding/Billing Information... 8 References... 8 Effective Date... 1/1/2018
More informationDefining the Emetogenicity of Cancer Chemotherapy Regimens: Relevance to Clinical Practice
Defining the Emetogenicity of Cancer Chemotherapy Regimens: Relevance to Clinical Practice PAUL J. HESKETH St. Elizabeth s Medical Center, Boston, Massachusetts, USA Key Words. Chemotherapy Emesis Emetogenicity
More informationComplications of the Systemic Treatment of Cancer
Complications of the Systemic Treatment of Cancer An Introduction to Acute Oncology July 2015 Aims and Objectives To be aware of the range of systemic therapies used in modern cancer care To list the potential
More informationPRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT
PRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT A collaboration between: St. Rocco s Hospice, Bridgewater Community Healthcare NHS Trust, NHS Warrington Clinical Commissioning Group,
More informationUsing a Simple Diary for Management of Nausea and Vomiting During Chemotherapy
Using a Simple Diary for Management of Nausea and Vomiting During Chemotherapy Problem identification Nausea and vomiting (N&V) are frequent complications following chemotherapy, even when taking 5-HT3
More informationClinical Policy: Aprepitant (Emend) Reference Number: CP.PMN.19 Effective Date: 11/06 Last Review Date: 08/17
Clinical Policy: (Emend) Reference Number: CP.PMN.19 Effective Date: 11/06 Last Review Date: 08/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationNausea and Vomiting Team. Outcome: Nausea and Vomiting. Scope of the Problem. Definition: Nausea
Nausea and Vomiting: The Continuing Battle to Improve Outcomes Jan Tipton, MSN, RN, AOCN Oncology CNS Medical University of Ohio Toledo, Ohio jtipton@meduohio.edu Nausea and Vomiting Team Jan Tipton, MSN,
More informationAlgorithms for Symptom Management. In End of Life Care
Algorithms for Symptom Management In End of Life Care The Use of Drugs Beyond Licence (off label) -The Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK regulates the activity of the
More informationpatient group direction
CYCLIZINE v01 1/7 CYCLIZINE PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner (Nurse)
More informationMANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE WHO ARE NIL BY MOUTH OR WITH A COMPROMISED SWALLOW
MANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE WHO ARE NIL BY MOUTH OR WITH A COMPROMISED SWALLOW Author: Gordon W Duncan Status: Approved Authorised by: Clinical Policy Group Version: 1.0 Review date:
More informationNausea. Assessment & Management. R J Crossno, MD, CMD, FAAFP, FAAHPM. Disclosures
Nausea Assessment & Management R J Crossno, MD, CMD, FAAFP, FAAHPM Disclosures Dr. Crossno discloses his employment as Area Medical Director for VistaCare VistaCare has provided commercial support for
More informationPVACE-BOP (Hodgkin s Lymphoma)
DRUG ADMINISTRATION SCHEDULE Day Drug Dose Route Diluent Rate 1 Ondansetron 8mg IV / Oral vinblastine 6mg/m 2 (Max: 10mg) IV Infusion Etoposide 100mg/m 2 IV infusion Patients over 65 years by 15 min infusion
More informationChemotherapy Induced Nausea and Vomiting
Chemotherapy Induced Nausea and Vomiting Aminah Jatoi, M.D. Professor of Oncology Mayo Clinic Rochester, Minnesota April 27, 2017 clinical and biologic fundamentals of chemotherapy induced nausea and vomiting
More informationPrevention and Management of chemo-and radiotherapy-induced nausea and vomiting
Prevention and Management of chemo-and radiotherapy-induced nausea and vomiting Focusing on the updated MASCC/ESMO guidelines Karin Jordan Department of Hematology and Oncology, University of Heidelberg
More informationSubject: Palonosetron Hydrochloride (Aloxi )
09-J0000-87 Original Effective Date: 02/15/09 Reviewed: 07/09/14 Revised: 03/15/18 Subject: Palonosetron Hydrochloride (Aloxi ) THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationPAIN MANAGEMENT Person established taking oral morphine or opioid naive.
PAIN MANAGEMENT Person established taking oral morphine or opioid naive. Important; it is the responsibility of the prescriber to ensure that guidelines are followed when prescribing opioids. Every member
More informationCardiac Catheter Labs Intravenous Drug Therapy Guide
Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Cardiac Catheter Lab IV Medicines Guideline Helen Buxton ( Senior Cath Lab
More informationMid Essex Locality Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care
Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care If possible patients should be assessed using a simple visual analogue scale VAS to determine the most appropriate stage
More informationSubject: Fosnetupitant-Palonosetron (Akynzeo) IV
09-J3000-01 Original Effective Date: 06/15/18 Reviewed: 05/09/18 Revised: 01/01/19 Subject: Fosnetupitant-Palonosetron (Akynzeo) IV THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION,
More informationANTIEMETIC GUIDELINES: MASCC/ESMO
Open Issues for CINV Do we reliably measure that? Do we control nausea optimally? Are guidelines useful for oral therapies related nausea and vomiting? Breakthrough and refractory nausea and vomiting:
More informationPalliative Prescribing - Pain
Palliative Prescribing - Pain LAURA BARNFIELD 21/2/17 Aims To understand the classes of painkillers available in palliative care To gain confidence in counselling regarding opiates To gain confidence prescribing
More informationRenal Palliative Care Last Days of Life
Renal Palliative Care Last Days of Life Introduction This guideline is an aid to clinical decision-making and good practice for patients with stage 4-5 chronic kidney disease (egfr
More informationWhy Patients Experience Nausea and Vomiting and What to Do About It
Why Patients Experience Nausea and Vomiting and What to Do About It Rebecca Clark-Snow, RN, BSN, OCN The University of Kansas Cancer Center Westwood, Kansas Multiple Roles for Supportive Care in Cancer
More informationMEDICAL NECESSITY GUIDELINE
PAGE: 1 of 10 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationClinical Tools and Resources for Self-Study and Patient Education
Clinical Tools and Resources for Self-Study and Patient Education CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING CLINICIAN'S RESOURCE GUIDE The clinical tools and resources contained herein are provided as educational
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT
European Medicines Agency Evaluation of Medicines for Human Use London, 17 February 2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON NON-CLINICAL AND CLINICAL DEVELOPMENT OF
More informationSymptom Management of Gastrointestinal Alterations
Symptom Management of Gastrointestinal Alterations Parisa Tsutsumi RN, BSN, OCN, BMTCN University of Washington Medical Center Nausea and Vomiting Mucositis Taste Alterations Gastrointestinal Alterations
More informationPAIN MANAGEMENT Patient established on oral morphine or opioid naive.
PAIN MANAGEMENT Patient established on oral morphine or opioid naive. Important; It is the responsibility of the prescriber to ensure that guidelines are followed when prescribing opioids. Every member
More informationAcute management of in-patient Parkinson s Disease patients
Acute management of in-patient Parkinson s Disease patients Contents Pages Introduction and Admission advice 2 Nil by Mouth Guidance 3 5 Complex therapy advice (Apomorphine, DBS, Duodopa) 6 Surgical peri-operative
More informationOral Granisetron for the Prevention of Acute Late Onset Nausea and Vomiting in Patients Treated with Moderately Emetogenic Chemotherapy
Oral Granisetron for the Prevention of Acute Late Onset Nausea and Vomiting in Patients Treated with Moderately Emetogenic Chemotherapy CARL J. FRIEDMAN, a HOWARD A. BURRIS III, b KAREN YOCOM, a LINDA
More informationAnticholinergic (Antimuscarinic) Guidelines. Treatment of Antipsychotic Induced Extra Pyramidal Side Effects (EPSE)
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire West Primary Care Alliance Anticholinergic (Antimuscarinic)
More informationSee references. All clinical staff working in paediatric haematology and oncology to include doctors, nurses and pharmacists.
Mucositis Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Guideline for the management of mucositis in children and young people receiving chemotherapy Contact
More informationpost-operative, nausea, vomiting, antiemetics
Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Directorate & Speciality Guideline for the prevention and treatment of Postoperative
More informationA RANDOMISED, OPEN LABEL STUDY OF GUIDELINE DRIVEN TARGETED ANTIEMETIC THERAPY VERSUS SINGLE AGENT ANTIEMETIC THERAPY
A RANDOMISED, OPEN LABEL STUDY OF GUIDELINE DRIVEN TARGETED ANTIEMETIC THERAPY VERSUS SINGLE AGENT ANTIEMETIC THERAPY Patsy Yates, Janet Hardy, Peter Martin, Jennifer Philip, Peter Hudson, David Currow,
More informationGuideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients
Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients POGO Antineoplastic Induced Nausea and Vomiting Guideline Development Panel: L.
More informationNausea and Vomiting. Symptom Management of Gastrointestinal Alterations. Gastrointestinal Alterations. Nausea/Vomiting Patterns
Symptom Management of Gastrointestinal Alterations Elise Frans, MN, RN, CWON Oncology Clinical Nurse Specialist University of Washington Medical Center delterzo@uw.edu Nausea and Vomiting Mucositis Taste
More informationNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Antiemesis. Version NCCN.org. Continue
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 1.2011 NCCN.org Continue Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that
More informationBJF Acute Pain Team Formulary Group
Title Analgesia Guidelines for Acute Pain Management (Adults) in BGH Document Type Issue no Clinical guideline Clinical Governance Support Team Use Issue date April 2013 Review date April 2015 Distribution
More informationCisplatin and Vinorelbine and radiotherapy (NSCLC)
Cisplatin and Vinorelbine and radiotherapy (NSCLC) Indication First-line chemotherapy for use with concomitant radical radiotherapy for early or locally advanced non-small cell carcinoma (NSCLC) ICD-10
More information